Clinical Trial Update: Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the response to KY1005 in adults with moderate-to-severe atopic dermatitis has completed, with results posted on 2025-07-03.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• KY1005

Snippet

Sponsor: Kymab Limited | Conditions: Eczema, Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2025-07-03